Zolgensma’s Pay Model Avoids Medicaid Best Price Pitfall

By John Wilkerson / May 30, 2019 at 2:57 PM

The pay model for the world’s most expensive drug, Zolgensma, lets insurers pay less for the gene therapy when it doesn’t work without triggering Medicaid best price, a policy that has frustrated development of value-based pay arrangements, said a spokesperson for Zolgensma’s maker AveXis.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.